Sanya Sukduang concentrates on patent litigation before federal district courts and the U.S. Court of Appeals for the Federal Circuit, primarily in the areas of biotechnology, pharmaceuticals, biologics, and medical devices. He has conducted all aspects of pre-trial, trial, and post-trial proceedings. Mr. Sukduang has extensive experience in cases arising from the filing of Abbreviated New Drug Applications (ANDA). He advises clients on an array of issues concerning biologics, including due diligence investigations, strategic patent portfolio planning, and reexaminations before the U.S. Patent and Trademark Office.
Mr. Sukduang lectures in the U.S. and abroad on biologics and biosimilars arising under the Biologics Price Competition and Innovation Act (BPCIA) and has authored numerous articles on this topic.
- Eli Lilly and Co. v. Wockhardt Ltd. (S.D. Ind.). Successfully represented Eli Lilly and Company in an ANDA litigation for its blockbuster drug Cymbalta® against multiple generic drug manufacturers, resulting in orders and judgment maintaining Cymbalta's® market exclusivity through the end of its patent life.
- Bonutti v. ConforMIS, Inc. (D. Del.). Lead counsel in obtaining a successful settlement for ConforMIS relating to customizable knee implants.
- Monsanto v. Syngenta (D. Del., Fed. Cir.). Represented Syngenta Seeds, Inc. in successfully obtaining summary judgment of non-infringement and invalidity regarding genetically modified corn.
- Boston Heart v. Health Diagnostic Laboratories (D. Mass.). Lead litigation and ex-parte reexam counsel in defending HDL against patent infringement allegations related to HDL's SLCO1B1 genetic test.
- Medac Pharma Inc. v. Antares Pharma Inc., (D. NJ). Lead litigation and IPR counsel for Antares defending against allegations of infringement concerning Antares' Otrexup® (subcutaneously injectable methotrexate).
- Forest Labs v. Apotex (D. Del.). Co-lead counsel representing Forest Labs in an ANDA litigation for its Savella® (milnacipran) product for the treatment of fibromyalgia against multiple generic manufacturers.
- Forest Labs v. Sigmapharm (D. Del.). Co-lead counsel representing Forest Labs in an ANDA litigation for its Saphris® (asenapine) product for the treatment of schizophrenia and bi-polar disorder against multiple generic manufacturers.
- Successfully represented a client in an ex parte reexam proceeding protecting clients' Factor VIII patent resulting in favorable multi-million dollar litigation settlement.
- Lead trial and appellate counsel in a pro bono adoption proceeding successfully assisting a foster mother's efforts to adopt her three year old foster daughter.
- Serves as an adjunct professor of Hatch-Waxman Litigation, Washington College of Law, 2013-present, and previously as an adjunct professor of Patent Law, Howard University Law School, 2007-2012.
- Serves as chair of Finnegan's Diversity and Inclusion Committee.
- Washington DC "Rising Star", 2013-2014; and "Super Lawyer", 2014, in Intellectual Property Litigation, Super Lawyers Magazine.
- Recipient of the National Asian Pacific American Bar Association's "Best Lawyers Under 40," 2013.
- "Intellectual Property: Life Sciences Star", LMG Life Sciences, 2012-2014.
- Recipient of Eli Lilly and Company's "Quality Advocate Award," 2011.
- Asian Pacific American Bar Association (chair of partner’s forum, 2008-2009; newsletter editor, 2007-2008; secretary 2006-2007; vice-president of programs, 2003-2006)
- Maryland Patent Law Association (president 2005-present; vice president, 2001-2005)
- Asian Pacific American Bar Association Education Fund (Board of Directors, 2000-2002)
- Washington College of Law, Dean’s Diversity Counsel (Board of Directors, 2002-present)
- American Intellectual Property Law Association
- Coauthor. "Zarxio's® Approval: Some Insights and Unanswered Questions Regarding the Future of U.S. Biosimilars," AIPLA Food and Drug Committee Newsletter, March 2015.
- Coauthor. "Leveraging the U.S. Design Patent System to Protect Innovative Product Designs," ABPI Magazine, July/August 2014.
- Coauthor. "Inter Partes Review in Generic Drug Litigation—Why the USPTO Should Exercise Its Discretion to Deny IPR Petitions in Appropriate Hatch-Waxman Act Disputes," pharmaphorum, March 7, 2014.
- Coauthor. "Drug Patents Under Fire in Brazil," Pharmaceutical Executive, June 4, 2013.
- Coauthor. "Assessing Materiality and Intent in a Post-Therasense World," BNA's Patent, Trademark & Copyright Journal, Feb. 15, 2013.
- Coauthor. "Summary of FDA Public Hearing Regarding Draft Guidances Relating to the Development of Biosimilar Products," Finnegan IP Update, May 17, 2012.
- Coauthor. "A Summary of the Supreme Court's Prometheus Decision," Finnegan IP Update, March 21, 2012.
- Coauthor. "Summary of FDA Draft Guidance on BPCIA," Finnegan IP Update, March 16, 2012.
- "FDA's Proposed Performance Goals for Biosimilar Applications May Provide Some Certainty for Biologics Companies," Bloomberg Law Reports, June 7, 2011.
- Coauthor. "The FDA's Hearing on Biosimilars: What Did We Learn?" Finnegan IP Update, Nov. 19, 2010.